Tuberc Respir Dis > Volume 45(5); 1998 > Article
Tuberculosis and Respiratory Diseases 1998;45(5):962-974.
DOI: https://doi.org/10.4046/trd.1998.45.5.962    Published online October 1, 1998.
Prognostic Value of the Expression of p53 and bcl-2 in Non-Small Cell Lung Cancer.
Seok Chul Yang, Ho Joo Yoon, Dong Ho Shin, Sung Soo Park, Jung Hee Lee, Joo Seob Keun, Gu Kong, Jung Dal Lee
1Department of Internal Medicine, College of Medicine, Hanyang University, Seoul, Korea.
2Department of Pathology, College of Medicine, Hanyang University, Seoul, Korea.
3Department of Pathology, College of Medicine, SungKyunKwan University, Seoul, Korea.
Abstract
BACKGROUND
Alteration of p53 tumor suppressor genes is most frequently identified in human neoplasms, including lung carcinoma. It is well known that bcl-2 oncoprotein protects eel]s from apoptosis. Recent studies have demonstrated that bcl-2 expression is associated with favorable prognosis for patients with non-small cell lung carcinoma. However, the precise biologic role of bcl-2 in the development of these tumors is sri]1 obscure. p53 and bcl-2 have important regulatory influence in the apoptotic pathway and thus their relationship is of interest in tumorigenesis, especially lung cancer. Purpose : The author investigated to know the prognostic significance of the expression of p53 and bcl-2 in radically resected non-small cell lung cancer. Method : 84 cases of formalin-fixed paraffin-embedded blocks from resected primary non-small cell lung cancer from 1980 to 1994 at Hanyang University Hospital were available for both clinical follow-up and immunohistochemical staining using monoclonal antibodies for p53 and bcl-2. RESULTS: The histologic classification of the tumor was based on WHO criteria, and the specimens included 45 squamous cell carcinomas(53.6%), 28 adeonocarcinomas(33.3%) and 11 large cell carcinomas(13.1%). p53 immunoreactivity was noted in 47 cases of 84 cases (56.0%). bcl-2 immunoreactivity was noted in 15 cases of 84 cases (17.9%). The mean survival duration was 64.23 +/- 10.73 months in bcl-2 positive group and 35.28 +/- 4.39 months in bcl-2 negative group. The bcl-2 expression was significantly correlated with survival in radically resected non-small cell lung cancer patients(p=0.03). The mean survival duration was 34.71 +/- 6.12 months in p53 positive group and 45.35 +/- 6.30 months in p53 negative group(p=0.21). The p53 expression was not predictive for survival. There was no correlation between combination of the different status of p53 and bcl-2pression in our study. CONCLUSIONS: The interaction and the regulation of new biologic markers, such as those involved in the apoptotic pathway, are complex. bcl-2 overexpression is a good prognostic factor in non-small cell lung cancer and p53 expression is not significantly associated with the prognostic factor in non-small co]1 lung cancer.
Key Words: Non-small cell lung cancer, Survival, p53, bcl-2


ABOUT
ARTICLE & TOPICS
Article category

Browse all articles >

Topics

Browse all articles >

BROWSE ARTICLES
FOR CONTRIBUTORS
Editorial Office
101-605, 58, Banpo-daero, Seocho-gu (Seocho-dong, Seocho Art-Xi), Seoul 06652, Korea
Tel: +82-2-575-3825, +82-2-576-5347    Fax: +82-2-572-6683    E-mail: katrdsubmit@lungkorea.org                

Copyright © 2024 by The Korean Academy of Tuberculosis and Respiratory Diseases. All rights reserved.

Developed in M2PI

Close layer
prev next